Fintel reports that on November 4, 2024, Argus Research upgraded their outlook for AbbVie (NYSE:ABBV) from Hold to Buy.

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

The University of Chicago Medicine’s incoming cancer center is getting a new name thanks to a $75 million donation from the ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $203.55 which represents a decrease of $-0.32 or -0.16% from the prior close of $203.87. The stock opened at $204.37 and touched a ...

EvolveImmune Therapeutics Inc., a Branford-based bioscience company developing therapeutics to overcome cancer cell resistance to current immunotherapies, has signed a collaboration and ...

Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.

Their discoveries have already led to the departure of a Stanford president, sparked charges from the Department of Justice, ...

Argus upgraded AbbVie (ABBV) to Buy from Hold with a $220 price target Two of the company’s key immunology products, Skyrizi and Rinvoq, have succeeded Humira as growth engines, with the former having ...

(Reuters) -Cigna projected 2025 profit growth of at least 10% on Thursday, after posting quarterly results that beat Wall ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

AbbVie has entered into a partnership and option-to-license agreement with EvolveImmune Therapeutics, to develop ...